Security
City Therapeutics, Inc. Common Stock · CTY
CTYNASDAQCommon stockCurrentCIK 2143850Updated Nov 11, 2026
CTY price & chart
Loading TradingView…
NASDAQ:CTY on TradingView ↗About the company
We are a clinical-stage biotechnology company developing the next generation of RNA interference (“RNAi”) therapeutics designed to silence the expression of disease-relevant proteins, with the aim of delivering meaningful and durable benefits for patients in need. We believe our deep RNAi expertise and City Platform capabilities uniquely position us to achieve our goal of developing potentially best-in-class therapeutics. Our vision is to lead the next generation of RNAi therapeutics, and our mission is to improve patients’ lives through breakthrough RNAi science as we build a biopharmaceutical company with enduring impact.
In the news
No coverage from other publishers is available.
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
SCHEDULE 13G - filed by FMR LLC regarding CITY THERAPEUTICS, INC.
SCHEDULE 13D - filed by ARCH Venture Fund XII, L.P. regarding CITY THERAPEUTICS, INC.
SCHEDULE 13G - filed by VIKING GLOBAL INVESTORS LP regarding CITY THERAPEUTICS, INC.
SCHEDULE 13G - filed by Invus Global Management, LLC regarding CITY THERAPEUTICS, INC.
Offerings
Registration 333-299117
- Gross proceeds
- 199999998.0
- Net proceeds
- 185999998.0
- Deal price
- 18.0
- Shares
- 11111111
- Offering price
- $18.00
- Ticker
- CTY
Underwriters: Goldman Sachs & Co. LLC, Jefferies, Stifel, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, Oppenheimer & Co. Inc.
Registration 333-299481
Filing attachments
tm2629408d1_ex99-1.htm · 8-K · 2026-11-10
Exhibit 99.1 City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease CITY-RBP4 is an RNAi therapeutic candidate designed to provide potent and durable suppression of RBP4, a clinically supported target in Stargardt disease City’s second program to advance into the clinic, demonstrating strong momentum across the pipeline CAMBRIDGE, Mass., November 10, 2026 - City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biote…
Read attachment ↗ormp-ex99_1.htm · SCHEDULE 13D · 2026-10-26
Exhibit 1 AGREEMENT Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of City Therapeutics, Inc. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original. Dated: October 26, 2026 ARCH VENTURE FUND XII, L.P. By: ARCH Venture Partn…
Read attachment ↗tm2619715d6_ex4-1.htm · S-1 · 2026-09-24
Exhibit 4.1 THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND REGISTRAR, FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF City Therapeutics, Inc. (hereinafter called the “Company”), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. This Certificate and the shares represented hereby, are issued and sha…
Read attachment ↗tm2619715d6_ex4-2.htm · S-1 · 2026-09-24
Exhibit 4.2 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of May 20, 2026, by and among City Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. RECITALS WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of Series A Preferred Stock, Series Seed Preferred St…
Read attachment ↗